Summary: Biologic drug substance development and biomanufacturing is a critical step in the long, complex pathway to approval. There are many considerations to be made around...

Summary: Learn about specific case studies for neuromuscular degenerative indications, AAV technology and manufacturing, strategies for navigating the current regulatory environments.

Summary: Allogeneic T-cell therapies are moving towards having breakthrough therapies available for market launch.

Summary: Learn about Catalent’s journey into the Cell and Gene therapy space, overcoming challenges, and the company’s commitment to its partners. 

Summary: R&D execs discuss how they've reorganized global teams, tapped new programs to fight COVID-19 and plan for the future after the pandemic.

Summary: What hurdles need to be overcome before gene therapy is the new modality in the cancer therapy arsenal? We’ll look at manufacturing, viral vectors, and the most promising approaches coming to the clinic.

Summary: Experts and executives break down the biggest data that came out during the American Society of Clinical Oncology (ASCO) virtual conference 2020.

Summary: Catalent and LumaCyte experts collaborate to compare AAV production with three different transfection reagents.

Summary: Maximizing the therapeutic window and manufacturing well-defined ADCs are major challenges in the clinical development of ADCs. During this webinar, experts from Triphase Accelerator and...

Summary: This case study explores Catalent’s unique GPEx® technology for stable gene product expression with Berkeley Lights, Inc.’s (BLI) Beacon® instrument for clonal selection.